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Abstract
The clinical presentations of atherosclerotic disease are the result of a constella-
tion of diverse metabolic and immunologic mechanisms ultimately set into motion 
by the formation of fatty acid streaks and the accompanying inflammatory cell 
activation, endothelial damage, smooth muscle proliferation, vascular fibrosis, and 
end-organ infarction and necrosis. At the heart of atherosclerosis are the byprod-
ucts of lipid metabolism, lipoproteins containing triglycerides, phospholipids, 
and cholesterol, and the changes they undergo that eventually lead to macrophage 
activation, foam cell formation, and other downstream atherosclerotic changes. 
Understanding the functionality of cholesterol, triglycerides, and lipoproteins in the 
cascade of atherosclerotic pathways has tremendous implications on current guide-
lines for the evaluation and targets in the management of dyslipidemia, and serves 
as the foundation for future investigations into targets of atherosclerotic therapies.
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1. Introduction
Atherosclerosis, the pathogenic process of vascular lipid deposition, arterial 
luminal narrowing, and plaque expansion and instability, represents the major 
driver of circulatory morbidity and mortality, including myocardial infarction, 
ischemic cardiomyopathy, transient ischemic attacks, and ischemic and hemor-
rhagic stroke [1]. The acute and chronic clinical presentations of atherosclerotic 
disease are the result of a constellation of diverse metabolic and immunologic 
mechanisms ultimately set into motion by the formation of fatty acid streaks and 
the accompanying inflammatory cell activation, endothelial damage, smooth 
muscle proliferation, vascular fibrosis, and end-organ infarction and necrosis [2]. 
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At the heart of atherosclerosis are the byproducts of lipid metabolism, lipoproteins 
containing triglycerides, phospholipids, and cholesterol, and the changes they 
undergo that eventually lead to macrophage activation, foam cell formation, and 
other downstream atherosclerotic changes [3]. Lipoproteins are distinguished by 
their lipid content, their position in lipid metabolic pathways, and overall athero-
genic risk [4, 5]. This chapter will review the role that the various lipoproteins play 
in the pathophysiology of atherosclerosis as the fundamental triggers and players 
in the immunologic, inflammatory, and thrombotic processes that characterize the 
pathogenesis of atherosclerotic cardiovascular disease. Understanding the function-
ality of cholesterol, triglycerides, and lipoproteins in the cascade of atherosclerotic 
pathways has tremendous implications on current guidelines for the evaluation and 
targets in the management of dyslipidemia, and serves as the foundation for future 
investigations into targets of atherosclerotic therapies.
2. Lipoproteins and apolipoproteins
Lipoproteins are complex plasma particles containing a core of cholesterol esters 
and triglycerides surrounded by free cholesterol, phospholipids, and apolipopro-
teins, and are classified based on size, density, and major lipid and apolipoprotein 
content [6]. Apolipoproteins, structural proteins that bind triglyceride and choles-
terol and enable the formation of lipoproteins, enjoy important roles in lipoprotein 
structure and metabolism by acting as ligands for lipoprotein receptors and activa-
tors or inhibitors of enzymes involved in lipoprotein metabolism [6, 7]. The size, 
structure, and apolipoprotein content of the lipoproteins, namely chylomicrons 
(CM), very-low-density lipoprotein (VLDL), intermediate-density lipoprotein 
(IDL), low-density lipoprotein (LDL), high-density lipoprotein (HDL), and 
lipoprotein(a) [Lp(a)], crystallize into individualized atherosclerotic risk profiles 
for the specific lipoprotein [8, 9].
2.1 Chylomicrons and chylomicron remnants
CMs, the largest and least dense of the lipoproteins, are triglyceride rich, 
released from the intestine, and primarily responsible for delivery of dietary 
cholesterol and triglycerides to peripheral tissue and the liver [6, 10]. Removal of 
triglycerides from circulating CMs generates CM remnants that possess a consider-
ably higher cholesterol concentration [6, 11]. CMs and CM remnant size is linked to 
ingested triglyceride levels and the structure is maintained by multiple apolipopro-
teins, predominantly apolipoprotein B-48 (Apo B-48) [6]. Apo B-48 is synthesized 
in the intestine, and represents 48% of the amino acids in the peptide sequence of 
apolipoprotein B-100 (Apo B-100), the apolipoprotein synthesized by the liver and 
a major apolipoprotein involved in the atherosclerotic pathophysiology [12].
2.2  Very-low-density lipoprotein (VLDL) and intermediate-density lipoprotein 
(IDL)
Triglyceride consumption by adipose tissue and the resulting cholesterol-rich 
CM remnants subsequently reach the liver, which reorganizes triglycerides and 
cholesterol in the form of VLDL that are secreted into circulation and allow for 
lipoprotein lipase (LPL) mediated absorption of triglycerides by cardiomyocytes, 
skeletal muscle, and adipose tissue [4, 6]. CMs, CM remnants, and VLDL contain 
apolipoprotein C (Apo C), specifically Apo C-II, an essential cofactor for LPL, 
and transposition of triglycerides from circulating lipoproteins to tissue steadily 
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increases the concentration of cholesterol and overall density of the lipoprotein 
while simultaneously decreasing the size [6, 13]. The apolipoprotein that plays 
the most atherogenic role of all the apolipoproteins and distinguishes VLDL from 
chylomicrons and CM remnants is Apo B-100, a major structural apolipoprotein 
and LDL receptor (LDLR) ligand [6, 14]. VLDL exists as the bridge between the 
exogenous and endogenous pathways of lipid metabolism, with the lipid content 
of CM remnants that reach the liver via gastrointestinal absorption at the begin-
ning of the exogenous pathway being repackaged and secreted by hepatocytes as 
VLDL to initiate the endogenous pathway. IDLs, considered VLDL remnants, are 
considerably smaller than the antecedent VLDL and exhibit similar apolipoprotein 
composition, but they have similar triglyceride and cholesterol contents to the CM 
remnants [4, 14, 15]. The decreased size and cholesterol along with the appropriate 
apolipoprotein profile of Apo B-100 and Apo-E, another apolipoprotein ligand for 
the LDLR, make IDL atherogenic, but the primary atherogenic lipoprotein that sets 
off the cascade of atherosclerotic lipid, immunologic, and inflammatory pathways 
remains LDL (Table 1).
2.3 Low-density lipoprotein (LDL)
LDL, derived from LPL/Apo C-II-mediated triglyceride removal from VLDL 
and IDL, is the lipoprotein responsible for cholesterol transport to peripheral tissue 
and the lipoprotein that has been extensively studied and directly implicated in 
the development of atherosclerosis [4, 5]. With an average size of 18–25 nm, LDL 
and the predominant apolipoprotein it contains, Apo B-100, undergo oxidation 
and other molecular modifications that are responsible for endothelial damage, 
macrophage chemoattraction, and pathologic arterial changes [1, 6, 16]. Individual 
LDL particles can vary in size, with decreasing or small dense LDL being noticeably 
more atherogenic than large LDL particles due to susceptibility to oxidation, ease 
of extravasation and entrapment in the arterial wall, and avidity for binding with 
vascular wall proteoglycans [6, 16, 17].
The metabolism of LDL, and thus the circulatory availability and arterial wall 
extravasation ability of LDL, is determined by the quantity of hepatic LDLR, as the 
concentration of LDL generated from the metabolism of VLDL and IDL is regulated 
by the amount of IDL that is absorbed into the liver via the LDLR prior to LPL-
mediated triglyceride removal [6, 18]. Hepatic levels of LDLR are primarily modu-
lated by hepatocyte cholesterol levels, with adequate cholesterol levels stimulating 
Lipoprotein Size (nm) Major lipid content Apolipoproteins




30–75 Triglyceride, cholesterol Apo B-48, ApoE
VLDL 30–75 Triglyceride Apo B-100, Apo C, ApoE
IDL 25–35 Triglyceride, cholesterol Apo B-100, Apo C, ApoE
LDL <25 Cholesterol Apo B-100
Lp(a) 30 Cholesterol Apo B-100, Apo(a)





Lipoproteins—size, lipid, and apolipoprotein content.
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LDLR targeting for degradation by PCSK9, a protein synthesized by hepatocytes 
that binds the LDLR and promotes lysosomal LDLR degradation [5, 6, 19].
LDL subfraction sizes and the resulting atherogenicity need to be considered 
when evaluating patients, as therapeutic regimens (such as niacin) have been known 
to affect LDL particle size. It is also important to realize that while overall cholesterol 
panel level changes may occur and appear to be in the right direction, it is actually 
the atherogenicity of the particles specifically of LDL that drives the pathogenesis of 
atherosclerosis [20]. Analysis, therefore, of LDL subfractions may be an important 
component of lipid follow-up in patients with complex lipid disorders on combina-
tion pharmacologic therapy.
2.4 High-density lipoprotein (HDL)
HDL differs from VLDL, IDL, and LDL in size, lipid, and apolipoprotein con-
tent, role in cholesterol metabolic pathways, and antiatherogenic characteristics. 
HDL is responsible for peripheral cholesterol uptake and delivery to the liver- and 
cholesterol-derived hormone-producing organs, and it provides important anti-
oxidant and anti-inflammatory functions that can inhibit atherosclerosis [4, 6, 21]. 
Devoid of Apo B-100 that contributes to LDL oxidation and subsequent macro-
phage activation, HDL is associated with multiple subtypes of apolipoprotein A 
(Apo A) that facilitates cholesterol transfer from peripheral tissue and activates 
lecithin-cholesterol acyltransferance (LCAT), which allows for cholesterol esteri-
fication and movement of cholesterol from the HDL surface to the HDL core 
[6, 22]. After cholesterol uptake from peripheral tissue and macrophages, HDL 
facilitates transfer to the liver via scavenger receptor class B type I (SR-B1), where 
the cholesterol can be converted into bile acids for excretion or be directly secreted 
into bile [21, 23]. The apolipoprotein profile and receptors involved in cholesterol 
movement from HDL sheds light on some of the physiologic pathways involved in 
HDL attenuation of atherosclerosis and conversely the highly atherogenic contents 
and formulation of LDL.
2.5 Lipoprotein A [Lp(a)]
Lp(a) is the lipoprotein formed of a cholesterol-rich LDL molecule and apolipo-
protein a [Apo(a)], with levels that are very fluctuant but are generally dependent 
on the rates of hepatic production of Apo(a) [6, 24]. The Apo-B100 and the Apo(a) 
are connected via a disulfide bond, and given its size and cholesterol composition 
essentially identical to that of LDL, Lp(a) is able to extravasate from plasma into the 
arterial intima and interact with the extracellular matrix through LDL Apo B-100 
and Lp(a) [24–26]. In addition to Lp(a), extracellular matrix interactions that facili-
tate the trapping of cholesterol that sets the table for macrophage uptake and foam 
cell formation, Lp(a) disrupts fibrinolysis and enhances coagulation, two functions 
that promote atherosclerotic plaque instability and rupture [24, 27].
3. Lipoproteins and the atherosclerotic thrombo-inflammatory process
3.1 Endothelial changes and regional plaque distribution
Endothelial cells undergo a series of changes, both connected and unrelated to 
lipoproteins that contribute to the different pathophysiologic mechanisms at play in 
atherosclerosis and help to explain the typical regional distributions of atheroscle-
rotic lesions.
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While LDL and other small and atherogenic lipoproteins undergo oxidative and 
structural changes that eventually lead to trapping in the arterial intima that recruit 
macrophages and other inflammatory cells, access to the intima extracellular matrix 
is spearheaded by endothelial cell dysfunction and damage from oxidative injury 
in conditions like smoking and hypertension, advanced glycation end products 
in diabetes mellitus, and regional hemodynamic forces in particular parts of the 
arterial tree [1, 28]. Oxidative insults to the endothelium impair production of nitric 
oxide (NO), the potent modulator of vascular tone and inhibitor of the prolifera-
tion of vascular smooth muscle cells (VSMCs), and exhibits important roles in the 
prevention of LDL oxidation and leukocyte extravasation from the bloodstream 
to arterial intima [29]. Additional chemical mediators of endothelial dysfunction 
include endothelin-1 (ET1) that interacts with NO in the regulation of arterial 
tone, signals changes in endothelial expression of adhesion molecules, and recruits 
important inflammatory cells such as macrophages while simultaneously regulating 
extracellular matrix enzymes that contribute to intimal alterations [1, 30].
The endothelial changes that best illuminate the regional pathophysiology 
of atherosclerosis are not the different levels of NO and other molecular signals, 
but the regional reorganization of endothelial phenotypes in reaction to local 
hemodynamic forces. Atherosclerotic plaques generally form at areas of arterial 
curvature and bifurcation, the locations in the arterial circulation where there are 
typical patterns of elevated shear stress [31]. Endothelial cells in regions of higher 
shear stress display a cuboidal morphology, higher cell turnover, and impaired 
endothelial barrier function that collectively promotes lipoprotein and inflamma-
tory cell migration, in comparison to endothelial cells in arterial beds with more 
favorable hemodynamics that exhibit ellipsoidal morphology, coaxial alignment, 
and an endothelial glycocalyx that protects against lipoprotein extravasation 
[31–33].
While the size, oxidative profiles, and atherogenic risk of the lipoproteins, most 
significantly LDL and Apo B-100, are the primary drivers of atherosclerosis, critical 
endothelial changes that further exacerbate the migration of lipoproteins, leuko-
cytes, VSMCs, and fibroblasts are fundamental to the generation of plaques and the 
clinical consequences of plaque expansion and rupture.
3.2 Initiation of the atherosclerotic plaque: foam cell formation
With continued endothelial compromise in regions of arterial curvature and 
bifurcation, circulating LDL, and to a lesser degree VLDL and IDL, increasingly 
migrate from the plasma and are retained in the extracellular matrix of the tunica 
intima [34, 35]. Subendothelial accumulation of LDL and VLDL remnants pre-
cipitates endothelial activation of the nuclear factor kappa B (NF-κB) pathway 
that enhances endothelial expression of adhesion proteins such as VCAM-1 and 
P-selection and pro-inflammatory receptors and cytokines that promote monocyte 
migration [32, 34, 36, 37]. As LDL, VLDL, VLDL remnants, IDL, and Lp(a) collect 
in the arterial intima, Apo B-100, most significantly in LDL, undergoes oxida-
tion to ox-LDL, a potent ligand of macrophage scavenger receptors [1, 5, 24, 38]. 
Endothelial activation and upregulation of adhesion molecules enables monocyte 
rolling, activation, and transendothelial migration where they differentiate from 
monocytes into macrophages [34, 39]. Retained ox-LDL interacts with two mac-
rophage receptors, class A and B scavenger receptors, and in distinct contrast to 
cholesterol absorbed via the LDLR by the macrophage, ox-LDL does not cause a 
negative feedback on scavenger receptor expression, perpetuating continued ox-
LDL and cholesterol uptake, resulting in the entrapment of newly formed foam cells 
in the arterial intima secondary to compromised mobility [1, 34, 39, 40].
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Despite the predominance of LDL in the cycle of endothelial damage, macro-
phage absorption, foam cell formation, and inflammatory transduction, VLDL 
and Lp(a) play important roles in endothelial activation [4, 24]. Endothelial cell 
exposure to the triglycerides of VLDL stimulates expression of selectins and other 
proteins that promote monocyte entry into the arterial intima, and oxidized 
VLDL increases expression of plasminogen activator inhibitor 1 (PAI-1), a protein 
that attenuates plasminogen conversion to plasmin and thus plasmin-mediated 
dismantling of cholesterol aggregates [4, 41, 42]. Lp(a) interactions with certain 
macrophage surface integrin proteins promote monocyte extravasation and upon 
macrophage absorption, upregulates expression of IL-1, tumor necrosis factor 
(TNF) and monocyte chemoattractant protein (MCP-1) that recruits additional 
macrophages, resulting in formation of more foam cells [24, 43].
3.3 Plaque development: inflammatory cells and smooth muscle cells
In addition to uptake by macrophages, ox-LDL acts as an omnipotent chemo-
kine that induces the activity of multiple immunologic pathways and leads to the 
migration and activation of additional monocytes and other inflammatory cells and 
VSMCs [1, 32, 44]. While LDL, VLDL remnants, IDL, and Lp(a) retention leads to 
foam cell formation as the integral first step in plaque development, subsequent leu-
kocyte adhesion and extravasation promotes clearance of foam cells and apoptotic 
cell debris from dendritic cells and T cells via a complicated interaction between 
the innate and adaptive immune systems [33, 45–47]. Atherosclerotic lesion mac-
rophages differentiating into inflammatory M1 macrophages present antigens to 
T cells, with resulting T cell activation and release of pro-inflammatory cytokines 
such as IL-1 and IL-6, inducing local lesion inflammation, further foam cell forma-
tion, and subsequent foam cell apoptosis and necrosis (Figure 1) [1, 48, 49].
In a similar pattern to macrophages, foam cells undergo phagocytosis by den-
dritic cells, where antigen presentation to T cells promotes release of pro-inflam-
matory cytokine, and continued phagocytosis compromises dendritic cell mobility 
resulting in dendritic foam cell formation [45, 50, 51].
The cascade of endothelial dysfunction, lipoprotein accumulation, and inflam-
matory pathways results in dramatic changes in VSMC physiology [32, 52]. Native 
arterial media VSMCs are activated and undergo proliferation, migration, and 
phenotypic switching that ultimately plays the most critical roles in atherosclerotic 
plaque stability or vulnerability [52–54]. VSMC proliferation and migration results 
in increased production of extracellular matrix components, such as proteoglycans 
and elastin, that attempts to compensate for the inward architectural distortions 
caused by subendothelial lipoprotein accumulation, causing outward vascular 
remodeling [32, 34, 55]. Collagen production by VSMCs is the most critical compo-
nent in the development of the fibrous cap in atherosclerotic plaques, with TGF-β 
released from plaque macrophages signaling VSMC proliferation [34, 56, 57].
3.4 HDL and plaque development
The multifaceted pathways of atherosclerotic plaque development and the role 
LDL and other Apo B-100 lipoproteins serve as a template for the important roles 
and diverse protective mechanisms and functions of HDL in the pathogenesis 
of atherosclerosis. Oxidation of Apo-B100 and the resulting accumulation and 
macrophage phagocytosis of LDL and other lipoproteins can be mitigated by the 
antioxidant activity of HDL, with its major apolipoproteins, Apo A-I and Apo A-II, 
and HDL-associated enzymes such as paraoxonase possessing antioxidant activity 
[21, 58, 59]. Resolving oxidative stress allows HDL to normalize endothelial function 
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by restoring production of NO [23, 60, 61]. HDL disrupts monocyte migration into 
the arterial intima via inhibition of endothelial cell adhesion protein expression, 
the fundamental first step in the formation of foam cells [62, 63]. HDL also inhibits 
VSMC migration and mitigates coagulation system and platelet activation, which 
come more into play in acute plaque rupture [4, 21, 64].
The major roles of HDL in atherosclerotic plaque development are inhibiting 
foam cell formation by promoting cholesterol transfer from macrophages and atten-
uating local lesion inflammation. In a pattern similar to normal reverse cholesterol 
transport from peripheral tissue to hepatocytes, HDL can remove cholesterol from 
macrophages and foam cells in the arterial intima via passive aqueous diffusion or 
cholesterol transporters, such as ATP-binding cassette transporters A1 (ABCA1) 
and G1 (ABCG1) and scavenger-receptor BI (SR-BI) that utilize the cholesterol 
concentration gradient [34, 65, 66]. HDL inhibits the M1 phenotype inflammatory 
macrophages that dominate in atherosclerotic plaques and present antigens to T 
cells while promoting M2 anti-inflammatory macrophages and modulating apopto-
sis of foam cells via antiapoptotic signaling pathways [67–69].
4. Atherosclerotic plaque progression, stability, and acute rupture
4.1 Plaque progression: fibrous cap and necrotic lipid core
Smooth muscle proliferation within the atherosclerotic plaque is characterized 
by the production of a subendothelial complex extracellular matrix making up the 
Figure 1. 
Small lipoproteins, most prominent LDL, penetrate the dysfunctional endothelial barrier and accumulate 
in the arterial intima. LDL (Apo B-100 apolipoprotein component) undergoes oxidation to ox-LDL, which 
triggers inflammatory cascade promoting migration of monocytes, VSMCs, and CD4 and CD8 T cells. ox-LDL 
undergoes phagocytosis by macrophages (and VSMCs) to generate foam cells. Insufficient clearance of apoptotic 
foam and inflammatory cells causes steady accumulation of subendothelial lipid necrotic core, which serves as 
central component of developing atherosclerotic plaque.
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fibrous cap that acts to wall off the inflammatory and highly thrombotic lesion col-
lection of cholesterol and cell debris that results from immune-mediated apoptosis 
and destruction of foam cells [1, 70, 71].
As the plaque progresses, the thickening of the intima and the pathologic expansion 
into the lumen displays areas of distinct cellular and lipid content, with the mature fibro-
atheroma consisting of an acellular lipid necrotic core of cell debris [71, 76]. The lipid 
component of the necrotic core consists of foam cells and newly free cholesterol from 
apoptotic macrophages that have been ineffectively cleared by efferocytosis [1, 71–73]. 
The necrotic lipid core can undergo steady expansion with resulting plaque enlargement 
and decreasing arterial lumen caliber due to diminished clearance capacity of cholesterol 
by VSMCs and advanced plaque macrophages [34, 74].
The steady accumulation of free cholesterol and lipid material alongside necrotic 
cellular products from apoptosis generates a continuous release of pro-inflammatory 
stimuli that further promote additional foam cell destruction, a vicious cycle that is 
contained by the thick collagenous fibrous cap [71, 75]. Vascular remodeling coun-
terbalances this continuous inflammatory process defined by intimal accumulation 
and lesion expansion, which minimizes protrusion into the lumen and mitigates 
clinical symptomology over the lifetime of the lesion (Figure 2) [34, 71, 76].
4.2 Stable and vulnerable plaques
The structural makeup of the plaque and relationship between fibrous cap thickness, 
lipid and necrotic core size, inflammatory activity, and overlying endothelial integrity 
translate to overall atherosclerotic plaque stability and risk of plaque compromise.
Figure 2. 
Steady development of the necrotic lipid core leads to subendothelial expansion, which over time narrows the 
diameter of the arterial lumen. VSMC migration, proliferation, and activation lead to deposition of fibrous 
collagenous extracellular matrix material to create the fibrous cap of the atherosclerotic plaque. Overlying 
dysfunction endothelial changes and breaks in the barrier allow for exposure of the contents of the cap and core 
to interact with serum cells and proteins, leading to platelet adherence to intact but vulnerable plaques.
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In stable atherosclerotic plaques, low-grade inflammation enables VSMC enrich-
ment, which increases the percentage of the plaque that is made up of the collagenous 
fibrous cap [77, 78]. In general, the lines of demarcation between more stable and 
more vulnerable plaques tend to center around the ratio between the solid fibrous tis-
sue and the extracellular lipid necrotic tissue, with stable and clinically silent plaques 
typically displaying thick fibrous caps and minimal to no extracellular lipid and 
necrotic foam cell debris [77, 79, 80]. While fibrous cap thickness and strength is a 
critical determinant of overall plaque stability, the fibrous tissue laid down by VSMC 
in the subendothelial part of the arterial intima is in a constant state of balance 
between collagen synthesis and degradation mediated by inflammatory cytokines 
that upregulate the expression of matrix metalloproteinases (MMPs) [1, 78, 81, 82]. 
MMPs can degrade fibrillar collagen, proteoglycans, and elastin over time, and the 
resulting thinning and structural compromise of the fibrous cap transitions the 
stable plaque to a vulnerable and high-risk plaque [77, 78, 83].
In parallel to the changes in the fibrous cap are dynamic swings in inflamma-
tory conditions in the necrotic lipid core, where increasing levels of VSMC and 
macrophage apoptosis not only decrease the net number of cells that can synthesize 
collagen and other stabilizing extracellular matrix components but also release 
additional inflammatory cytokines that can further destabilize the plaque [78, 84]. 
Similar to the roles played in plaque development, T cells, both T helper CD4 T cells 
and T cytotoxic CD8 cells, contribute to plaque destabilization via a perpetual loop 
of macrophage and T cell recruitment, lipid uptake, foam cell formation, antigen 
presentation, apoptosis, and lipid necrotic core expansion [78, 85, 86].
4.3 Rupture and erosion of vulnerable plaques and acute thrombosis
The nonresolving inflammatory processes of lipoprotein accumulation, foam 
cell formation, and immunologic activation leads to fibrocellular organization of 
the plaque, with the plaque becoming increasingly unstable and prone to rupture 
and acute thrombosis via fibrous cap thinning and lipid necrotic core expansion 
[34, 77, 87]. The fibrous cap is thinned and weakened by MMPs, and disruption of 
the collagenous cap and the overlying endothelium leads to exposure of the highly 
thrombogenic and coagulable lipid necrotic core [1, 88]. Atherosclerotic plaques, 
prior to any sort of structural compromise, are congregated by platelets that attach 
to the dysfunctional endothelium of the plaque, and can participate in plaque-
associated thrombosis with and without rupture or erosion [88, 89].
Ruptured and eroded plaques trigger a rapid and dramatic thrombotic and 
coagulation process, with activated platelets adhering to the exposed subendothelial 
collagen of the thin fibrous cap via interactions between von Willebrand factor 
(vWF) and glycoprotein (GP) Ib-V-IX, with adherent-activated platelets aggre-
gating via GP IIb/IIIa complexes [90–92]. After adhesion, activated-aggregated 
platelets release granules containing thromboxane A2, adenosine diphosphate 
(ADP), and other pro-thrombotic and pro-inflammatory cytokines that recruit 
inflammatory cells and amplify the platelet response (Figure 3) [1, 90, 93].
Alongside platelet activation and thrombus formation is activation of the coagu-
lation system, with tissue factor (TF) receptors in the plaque binding circulating 
factor VII(a) and triggering the extrinsic coagulation pathway to produce thrombin 
[90, 94, 95]. Thrombin, a strong platelet agonist via protease-activated receptor 
(PARs)-1 and 4, converts fibrinogen to fibrin for clot stabilization while simultane-
ously driving its own positive feedback loops through activation of factor XI and 
other factors in the intrinsic coagulation pathway [90, 96, 97].
The constellation of plaque rupture, platelet activation and aggregation, and 
coagulation system stimulation results in the formation of a thrombus on an 
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atherosclerotic plaque, causing partial to complete obstruction of the arterial 
lumen, which has already been narrowed steadily over time by plaque progression 
[1, 34, 90]. Postmortem pathological examination of these atherosclerotic plaque 
thrombi show a directional morphology that highlights the stepwise process of 
thrombus formation, with white platelet-rich heads adjacent to the focus of plaque 
rupture, with red extensions from the white platelet head to the distal arterial wall 
encompassing the fibrin and red blood cells that accumulate secondary to dimin-
ished blood flow from the obstructive thrombus [90, 98, 99].
5.  Atherosclerotic cardiovascular disease: presentation, evaluation, and 
management
5.1 Atherosclerotic cardiovascular disease (ASCVD)
ASCVD is the clinical manifestation of atherosclerosis and atherothrombosis, 
the resulting symptomology and physical findings of acute and chronic end-organ 
ischemia and infarction from the pathophysiologic thrombo-inflammatory pro-
cess of atherogenesis initiated by cholesterol and lipoprotein accumulation in the 
arterial intima. Public health appreciation and scientific evidence for the role of 
dyslipidemia in the progression of ASCVD has served as the impetus for organiza-
tions throughout the United States, Canada, and Europe to develop guidelines for 
evaluation and management of dyslipidemia and ASCVD [100–102]. Furthermore, 
the severity and associated morbidity and mortality of the clinical manifestations 
of ASCVD, including ischemic heart disease, such as stable angina, unstable angina, 
Figure 3. 
Rupture or erosion of the plaque’s fibrous cap enables exposure of highly thrombogenic and coagulable necrotic 
lipid core content to circulating platelets and coagulation factors. Acute atherothrombosis results with dramatic 
aggregation and activation of platelets and coagulation factors, resulting in acute occlusion of the implicated 
arterial tree and downstream tissue ischemia and necrosis.
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non-ST-elevation myocardial infarction (NSTEMI), and ST-elevation myocardial 
infarction (STEMI), peripheral artery disease (PAD), and cerebrovascular disease, 
both intracranial and extracranial, have prompted the development of condition 
specific guidelines for primary prevention, acute management, and secondary 
prevention [103–114]. Guidelines for management of dyslipidemia in the context of 
ASCVD are centered on the presence of pre-existing ASCVD, age, and underlying 
comorbidities, most prominently diabetes.
5.2 Coronary artery disease/ischemic heart disease
In the context of ASCVD, coronary artery disease (CAD), also referred to as 
ischemic heart disease (IHD), covers a spectrum of acute and chronic conditions 
resulting from myocardial oxygen demand and supply mismatch, generally caused 
by atherosclerotic disease of native coronary arteries, both fixed lesions and acute 
atherothrombosis [107, 115, 116].
Stable angina pectoris is a syndrome of recurrent and intermittent episodes of 
chest pain during instances of increased myocardial oxygen demand and insufficient 
oxygen supply from flow-limiting atherosclerotic coronary lesions [116, 117]. Stable 
angina is the initial clinical manifestation of nearly half of all patients with CAD, and 
given the high rates of myocardial infarction in patients with stable angina, extensive 
guidelines on workup and management, including stress testing, coronary calcium 
scoring by computed tomography, and cardiac catheterization and revascularization, 
to mitigate the risk of future major cardiovascular events [107, 117, 118].
Acute coronary syndrome (ACS), the acute manifestations of CAD, include 
unstable angina (UA), non-ST-elevation myocardial infarction (NSTEMI), and 
ST-elevation myocardial infarction (STEMI) are distinguished primarily by the 
absence of presence of electrocardiographic (EKG) changes and troponin elevation 
[115, 119]. The pathophysiology that differentiates stable angina from ACS is acute 
plaque rupture or erosion that results in the acute worsening of coronary artery 
flow, with subsequent symptomatic, electrocardiographic, and biochemical clinical 
findings ranging from moderate to severe chest pain all the way to acute cardiogenic 
shock and cardiac arrest [120, 121]. Myocardial infarction (MI), both NSTEMI and 
STEMI, caused by acute atherothrombotic disease of an eroded or ruptured plaque, 
is classified as a type I MI [115, 122]. It is distinguished from other etiologies of 
cardiomyocyte damage, troponin elevation, and EKG changes such as other acute 
stressors such as anemia, sepsis, or tachyarrhythmia that cause oxygen demand-
supply mismatch (type 2 MI), sudden cardiac death with symptoms suggestive of 
MI but no blood specimen available for troponin analysis (type 3 MI), type 4 MI 
as a complication of percutaneous coronary intervention (PCI), and type 5 MI as a 
complication of coronary artery bypass grafting (CABG) [115, 122–124]. The sever-
ity of clinical presentation, along with the acute and long-term risk after adequate 
management of ACS, has led to countless clinical trials and guideline recommenda-
tions on the acute management, involving antiplatelet and anticoagulation therapy, 
thrombolysis, PCI, and CABG [104–106, 125–127].
5.3 Cerebrovascular disease
Intracranial and extracranial atherosclerotic disease, the drivers of ischemic cere-
brovascular accident (CVA/stroke), can be the initial manifestation of atherosclerotic 
cardiovascular disease or can present concurrently with atherosclerotic disease in 
other arterial beds, including CAD or PAD [111, 112, 128]. Stroke is classified as either 
hemorrhagic or ischemic, with hemorrhagic stroke accounting for less than 20% of all 
strokes, with pathophysiology centered upon ruptured cerebral vessels that have been 
Dyslipidemia
12
damaged secondary to longstanding hypertension and amyloid angiopathy [129, 130]. 
While acute ischemic stroke can be caused by thromboembolic disease, particularly 
in the setting of atrial fibrillation, acute ischemic stroke is generally caused by acute 
thrombosis at the site of a cerebral atherosclerotic lesion, with neurologic motor and 
sensory manifestations in the anatomical distributions innervated by the affected 
region of the brain [112, 128, 131, 132]. In similar patterns to coronary artery disease, 
atherosclerotic cerebrovascular disease carries severely high rates of morbidity and 
mortality, with extensive evidence from clinical trials and guidelines directing highly 
time sensitive interventions, including thrombolysis and thrombectomy, and the 
general recommendations for primary and secondary prevention, including stroke-
related treatment of dyslipidemia [112, 113, 131, 133, 134].
5.4 Peripheral artery disease
While clinicians classically associated peripheral artery disease (PAD) with 
lower extremity atherosclerotic disease, PAD, also referred to as peripheral vas-
cular disease (PVD), encompasses atherosclerotic symptoms and disease of all 
non-coronary and non-cerebrovascular arterial trees, including the upper and 
lower extremities, renal, mesenteric, and aneurysms of the abdominal aorta and 
its branching vessels [103, 108, 135]. The pathophysiology and the clinical presen-
tation of PAD are directly related to the organ system or extremity perfused by 
the affected arterial tree, and similar to the contrast in stable angina versus acute 
coronary syndrome, the symptomology can be both acute and chronic.
Lower extremity PAD can manifest in different ways, with the classical symp-
tom of claudication affecting a very small to large portion of the lower extremity, 
with the affected area directly related to chronic arterial lumen narrowing from 
local atherosclerotic lesions and the proximal or distal positioning of the plaque 
[103, 136]. The most acute presentation of PAD is acute limb ischemia, the sudden 
loss of limb perfusion with associated symptoms typically of severe pain, can be 
caused by thromboembolism but more commonly is secondary to acute athero-
thrombosis from a ruptured or eroded atherosclerotic plaque [137–139]. Acute limb 
ischemia is distinct from critical limb ischemia (CLI), with CLI being classified 
alongside chronic PAD as CLI progresses over several weeks to months, with clinical 
symptoms of ischemic extremity pain at rest and/or development of ischemic tissue 
loss such as non-healing ulcers or gangrene [140–142]. The diagnosis and manage-
ment, both in the acute and chronic setting, involves assessing pulse and blood 
pressure differences between upper and lower extremities using the ankle-brachial 
index, vascular imaging, and revascularization, including thrombolysis, endovas-
cular repair, or open surgical correction [103, 108, 143–145].
Non-lower extremity PAD, including renal artery disease, mesenteric arterial 
disease, and aortic and branching vessel aneurysms represent additional manifesta-
tions of atherosclerotic cardiovascular disease with similar presentations of the 
acute and chronic natures.
Atherosclerotic renal arterial disease classically manifests as chronic renal disease, 
primarily presenting as a common cause of secondary hypertension from increased 
activation of the renin-angiotensin-aldosterone system [108, 146, 147]. Additionally, 
atherosclerotic renal arterial disease can appear as ischemic nephropathy with renal 
parenchymal disease and manifestations of renal failure from chronic hypoperfu-
sion, microvascular damage, and tubulointerstitial injury [146, 148]. Atherosclerotic 
renal arterial disease should be considered in patients with accelerated, resistant, 
or malignant hypertension with new onset acute renal failure or congestive heart 
failure, evaluated with renovascular imaging such as duplex ultrasonography 
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revascularization, both endovascular and surgical [108, 149–151]. Mesenteric isch-
emia can likewise present with chronic and acute symptoms, with chronic symptoms 
of abdominal pain with eating, classically referred to as intestinal or postprandial 
angina and representative of oxygen supply demand mismatch secondary to 
increased intestinal metabolic activity and diminished mesenteric arterial perfusion 
from underlying atherosclerosis flow-limiting lesions [108, 152]. Acute obstructive 
intestinal ischemia can be secondary to thromboembolism or to acute thrombosis of a 
ruptured or eroded atherosclerotic plaque, presenting classically with severe abdomi-
nal pain out of proportion to the physical exam, a critical condition that can result 
in bowel necrosis and acute abdomen [153, 154]. Given the associated morbidity 
and mortality, particularly of acute mesenteric ischemia, rapid general and vascular 
surgery consultation, with prompt diagnostic imaging and intervention is critical for 
appropriate evaluation and management [108, 155, 156].
Important components of the pathophysiology that promotes arterial lumen 
narrowing in atherosclerosis, namely chronic inflammation and extracellular 
matrix degradation initiated by oxidized lipoprotein accumulation, are critical pro-
cesses that contribute to development of abdominal aortic aneurysms (AAA) [157]. 
While the precise mechanism of atherosclerosis and its relationship to the develop-
ment of aneurysms of the abdominal aorta and its branch vessels is yet unclear, the 
high overlap of risk factors and similar pathophysiologic processes between the two 
conditions has prompted development of guidelines for monitoring and manage-
ment of dyslipidemia in patients with known AAA, along with appropriate surveil-
lance imaging for assessment of aneurysmal diameter [108, 158].
6.  Evaluation, management, and prevention of dyslipidemia and 
atherosclerosis
6.1  Cholesterol monitoring, LDL, and evolution of dyslipidemia cardiovascular 
risk algorithms
While the Apo B-100 cholesterol carrying lipoproteins all play roles in the 
pathogenesis of atherosclerosis through the critical initiating steps of arterial 
intima lipid accumulation and foam cell formation, cholesterol monitoring and 
assessment of atherosclerotic cardiovascular risk has centered around surveillance 
and management of serum LDL and LDL-cholesterol (LDL-C) levels based on the 
abundant evidence available from epidemiologic and genetic hypercholesterolemia 
studies, and randomized controlled trials [5, 159]. IDL, Lp(a), small VLDL, and 
VLDL remnants all possess the requisite diameter (<70 nm) and apolipoprotein 
profile (Apo B-100) to freely enter the arterial intima, undergo oxidation, and 
trigger macrophage phagocytosis, but LDL and LDL-C have been demonstrated to 
be the most atherogenic of the lipoproteins, with probability of LDL retention and 
risk of progressive plaque development increasing in parallel with LDL and LDL-C 
levels in dose-dependent manners [5, 35, 159]. Genetic studies of patients with 
familial hypercholesterolemia (FH), a spectrum of autosomal co-dominant dis-
orders with different loss or gain of function mutations involving genes involved 
in LDL metabolism, most commonly presenting as a loss of function mutation 
of the LDLR, carries a markedly increased risk for ASCVD in heterozygous FH 
patients, with the rare patients who are homozygous FH developing ASCVD as 
early as childhood and adolescence [5, 160, 161]. Large epidemiologic studies and 
meta-analyses have also demonstrated linear associations between LDL-C levels 
and risk of CAD death [5, 162]. The most compelling evidence for the association 
between LDL-C and ASCVD comes from the library of evidence from randomized 
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controlled clinical trials showing risk reduction of major cardiovascular events and 
progression of atherosclerotic plaques proportional to the decrease in LDL-C levels 
from statin and non-statin therapies [5, 163, 164]. Additionally, LDL subfrac-
tion sizes and the resulting atherogenicity need to be considered when evaluated 
patients, as studies have shown that while overall cholesterol panel levels may be 
ameliorated with therapy, it is the atherogenicity of the particles, specifically of 
LDL, that drives the pathogenesis of atherosclerosis [20]. Analysis, therefore, of 
LDL subfractions is likely an important component of lipid panel monitoring in 
these patients.
In parallel to the clinical studies and trials demonstrating the relationship between 
LDL, LDL-C, and ASCVD were the development of algorithms for the appropriate 
assessment and stratification of cardiovascular risk based on serum lipid profiles and 
other modifiable and non-modifiable cardiovascular risk factors, including age, gen-
der, family history, smoking, obesity, and hypertension [165, 166]. Multiple ASCVD 
risk algorithms exist both in the US and Europe, and include the Framingham 
Risk Score (FRS), the Reynolds Risk Score (RRS), the Systematic Coronary Risk 
Evaluation (SCORE), the QRisk2, and the American College of Cardiology/American 
Heart Association arteriosclerotic cardiovascular disease risk estimator (AC/
AHA-ASCVD) which has become the benchmark for risk stratification and clinical 
decision-making on cholesterol therapies [167].
Prior to the assessment of ASCVD risk and decisions on dyslipidemia therapy 
guidelines and recommendations for screening of cholesterol levels in adult 
patients who are asymptomatic and without history of ASCVD are employed. 
Differences exist in screening recommendations in the American, Canadian, 
and European dyslipidemia guidelines that were published in 2018, 2016, and 
2016, respectively [100–102]. Canadian and European guidelines propose that 
dyslipidemia screening be considered for men at or older than 40 years of age, 
but diverge on the initial age for women, with Canadian guidelines recommend-
ing at or older than 40 years of age, and European guidelines recommending at 
or older than 50 years of age [100, 102]. According to American guidelines, as 
recommended in the recently published “2018 AHA/ACC/ACCVPR/AAPA/ABC/
ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of 
Blood Cholesterol,” screening for LDL-C and non LDL-C can begin in adults as 
early as 20 years of age, or childhood or adolescence for patients with a history of 
FH [101].
6.2 Dyslipidemia: primary prevention of ASCVD
Compared to prior US cholesterol guidelines, the new 2018 ACC/AHA [101] 
guideline allows for more personalized targeted care for patients. By providing 
a guided approach to treatment for clinicians, they and their patients are given 
the tools necessary to understand and manage their risk related to cholesterol. 
Additionally, these revised guidelines highlight the importance of the “clinician-
patient discussion.” This patient risk discussion should include a review of risk 
enhancers to arrive at an appropriate share decision-making approach that 
addresses the patient’s values in terms of cost, potential for benefit, adverse effects, 
and drug-drug interactions.
The 2018 ACC/AHA guideline recommends that primary management of dyslip-
idemia for the primary prevention of ASCVD be considered for adult patients based 
on LDL-C levels and specific high-risk patient characteristics, most prominently a 
comorbid diagnosis of DM.
Anticholesterol therapy is indicated for adult patients with LDL-C greater than 
190 mg/dL or for selected patients with moderately high LDL-C levels greater than 
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160 mg/dL and a family history of premature ASCVD such as MI or CVA before 
55 years of age in a first-degree male relative or before 65 years of age in a first-
degree female relative (Figure 4).
Patients without LDL-C > 190 mg/dL or without LDL-C > 160 mg/dL and sig-
nificant family history of premature ASCVD are categorized based on the presence 
of DM and their 10-year ASCVD risk as estimated by their ASCVD score.
Special attention is paid to DM in the context of the primary prevention of ASCVD 
as DM is a major risk factor for ASCVD and contributes to and accelerates the patho-
genesis of atherosclerosis through multiple and diverse mechanisms [168, 169]. DM 
amplifies the immune response of key inflammatory cells, most critically macrophages, 
into the arterial intima in response to lipoprotein accumulation, and promotes the 
instability of atherosclerotic plaques by increasing the size of the necrotic lipid cores 
[169–171]. For adult patients, age 40–75 years, with DM, current guidelines recom-
mend initiation of moderate-intensity statin therapy with consideration for possible 
high-intensity statin therapy depending on patient’s individualized risk assessment.
For adult patients, age 40–75 years, without DM, decisions on lifestyle modifi-
cations and statin therapy are guided by the 10-year ASCVD risk as estimated by 
Figure 4. 
Management algorithm of dyslipidemia for primary prevention of ASCVD (adapted from 2018 AHA/ACC/





Management algorithm of dyslipidemia for secondary prevention of ASCVD (adapted from 2018 AHA/ACC/
ACCVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood 
Cholesterol).
the patient’s ASCVD score, with patients with a 10-year ASCVD risk score >7.5% 
qualifying for moderate-intensity statin therapy, and for patient’ with a 10-year 
ASCVD risk score >20% qualifying for moderate to high-intensity statin therapy. 
Beyond the 10-year ASCVD risk score, clinician-patient discussions of dyslipidemia 
and primary risk prevention should consider multiple factors, including patient 
preference, likelihood of statin side effects, prospective benefit of intensive lifestyle 
modifications, and presence or absence of risk-enhancing factors. Important risk-
enhancing factors to consider include metabolic syndrome, chronic kidney disease, 
chronic inflammatory or infectious conditions such as rheumatologic disease or 
HIV/AIDs, high-risk race or ethnicity, family history of premature ASCVD, and 
presence of lipid levels or biomarkers associated with increased ASCVD risk such as 
elevated Lp(a).
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6.3 Dyslipidemia: secondary prevention of ASCVD
Management of dyslipidemia for the secondary prevention of ASCVD is cen-
tered on encouragement of intensive healthy lifestyle modifications and risk assess-
ment for future ASCVD. Patients with high or very high-risk ASCVD are those with 
multiple major ASCVD events or one major ASCVD event and multiple high-risk 
conditions. Major ASCVD events include ACS within last 12 months, MI, ischemia 
CVA, PAD with claudication and ABI < 0.85, and PAD with previous revasculariza-
tion or amputation. High-risk conditions are similar to the risk-enhancing factors 
that were considered for the management of dyslipidemia in the context of primary 
prevention of ASCVD, and include age > 65, history of CABG or PCI outside of the 
major ASCVD events, DM, hypertension, chronic kidney disease, current smoking 
status, congestive heart failure, and persistently elevated LDL-C above 100 mg/dL 
despite maximal tolerate dose of statin therapy and ezetimibe, an anticholesterol 
drug that decreased small intestine absorption of cholesterol (Figure 5).
For patients with the aforementioned high-risk conditions who are on the maximal 
tolerated dose of statin therapy and ezetimibe with persistently elevated LDL-C > 70 
or non HDL-C > 100, the addition of PCSK9 inhibitors can be considered.
7. Current and future therapy targets for dyslipidemia ASCVD
7.1 Statins
Dyslipidemia therapy for the primary and secondary prevention of ASCVD, 
both current and therapies under investigation for future use, are centered on tar-
geting LDL-C given the extensive evidence demonstrating the relationship between 
LDL and ASCVD, and no class of medications has been shown to be more effective 
at lowering LDL-C than statins, the foundation of lipid and cholesterol lowering 
therapy [101, 172, 173].
Statins inhibit HMG-CoA reductase, the rate-limiting enzyme in the synthetic 
pathway of cholesterol, resulting in lowering of tissue cholesterol, most critically 
intrahepatic cholesterol, and reflex increase in hepatic expression of surface LDLR and 
accompanying enhancement of receptor-mediated uptake of LDL and other circulat-
ing lipoproteins [172, 174]. Beyond the inhibition of hepatic cholesterol synthesis and 
the resulting reduction in circulating LDL, statins have demonstrated other important 
benefits in atherosclerotic plaque progression and the risk of acute atherothrombosis 
[174, 175]. Statins promote plaque stabilization by reducing inflammation and increas-
ing collagen content in atherosclerotic plaques, slow the progression of overall plaque 
volume, and diminish high-risk or vulnerable plaque features [174–176].
Statin dosing intensity is categorized by expected reduction in LDL-C, with 
high-intensity statins typically lowering LDL-C by at least 50%, moderate-intensity 
statins typically lowering LDL-C by 30–49%, and low-intensity statins typically 
lowering LDL-C by less than 30%.
7.2 Nonstatins
There are different classes of non-statin medications used in the management 
of dyslipidemia, including bile acid sequestrants (cholestyramine, colestipol, and 
colesevelam), niacin, and fibrate, with ezetimibe and the PCSK9 inhibitors being 
the non-statin classes of medications that incorporated into the guidelines for 
dyslipidemia management in the primary and secondary prevention of ASCVD in 
combination therapy with statins [100].
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Ezetimibe decreases small intestine cholesterol absorption by inhibiting the 
Niemann-Pick C1-Like 1 (NPC1L1) transporter [172, 177]. While the exact mecha-
nisms of the effect of ezetimibe on atherosclerosis by itself are not as well defined 
as the effects of statins on atherosclerotic plaque progression and stabilization, the 
addition of ezetimibe to statins has been shown to regress plaque burden, reduce 
plaque volume, and promote plaque stabilization [178, 179]. PSCK9 works by 
interacting in with hepatic LDLR and enhancing the degradation of the receptor 
by hepatic lysosomes, with PSCK9 inhibitors thus mitigating the PSCK9-mediated 
turnover of hepatic LDLR and prolonging LDLR lifespan and uptake of circulating 
LDL-C [180]. PSCK9 inhibitors, namely alirocumab and evolocumab, in combina-
tion with statins have been shown to increase plaque calcification (a marker of 
plaque stability), and promote VSMC and collagen plaque content while simultane-
ously decreasing the size of the lipid necrotic core [181, 182].
7.3  New and future therapeutic targets and approaches to dyslipidemia and 
ASCVD
Beyond the dramatic reductions in LDL-C and mechanisms of atherosclerotic 
plaque stabilization and slowing of progression effected by statins, ezetimibe, and 
PSCK9 inhibitors and their codification in the management algorithms for dyslip-
idemia and ASCVD: the other inflammatory, lipoprotein, and metabolic pathways 
involved in the pathophysiology of atherosclerosis serve as potential targets for 
therapies in the primary and secondary prevention of dyslipidemia and ASCVD.
The antiatherogenic properties of HDL, both in terms of its antioxidant and choles-
terol efflux capacities, have led to investigations for the therapeutic potential of recon-
stituted HDL and methods to improve endogenous HDL functionality [23, 183]. Apo 
A-1 and apolipoprotein E (Apo E) are the atheroprotective apolipoprotein components 
of HDL, but studies involving Apo A-1/HDL mimetic peptides transcriptional upregu-
lators of Apo A-1 did not result in significant regression of coronary atherosclerotic 
lesions despite the enhanced HDL-C efflux [184]. Apo E consists of three isoforms 
(Apo E2, Apo E3, and Apo E4) and promotes clearance of circulating TG-rich lipopro-
tein remnants, cholesterol efflux from macrophages preventing foam cell formation, 
and diminishes expression of adhesion molecules necessary for macrophage migration 
into the arterial intima [184–186]. ApoE exerts additional atheroprotective functions 
via tampering the inflammatory response by inhibiting T cells, lipoprotein oxidation, 
and resulting proliferation and migration of VSMCs, suppressing platelet aggregation, 
and restoring endothelial function by promoting release of NO [184, 187–190]. Given 
ApoE diverse protective properties at various stages of the atherosclerotic thrombo-
inflammatory process, studies investigating the potential value of reconstituted HDL 
with favorable ApoE content or methods to promote increased ApoE profiles among 
endogenous HDL can serve substantial roles for the future management of dyslipid-
emia and ASCVD.
Given the extensive inflammatory pathways and processes underlying the patho-
genesis of atherosclerosis, considerable work has been and is currently dedicated 
to anti-inflammatory targets of therapy in dyslipidemia and ASCVD, with drugs in 
various stages of research and development. The role of lipoprotein oxidation, most 
significantly LDL to ox-LDL, has prompted the study of therapeutic antioxidants in 
the management of dyslipidemia, and has shown promising benefits in secondary 
prevention of ASCVD after ACS within 12 months [191, 192]. The increase of ox-LDL 
levels due to phospholipase A2 activity which enzymatically generate phospholipids 
with atherogenic modifications has led to study of the role of phospholipase 2 inhibi-
tors in the prevention of atherosclerosis [193]. Many other inflammatory pathway 
targets have been investigated for the management of dyslipidemia and ASCVD 
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including leukotriene pathway inhibitors (promote atherosclerotic plaque develop-
ment and progression via chemoattraction of macrophages and other inflammatory 
cells and increasing endothelial permeability), chemokine CC motif ligand 2 (CCL2), 
also known as MCP1 (chemokine recruiter of plaque destabilizing macrophages), 
and blockade of potent inflammatory markers TNF and IL-1 [191, 194–196].
8. Conclusion
Atherosclerotic cardiovascular disease encompasses conditions carrying tremen-
dous morbidity and mortality, and is the acute and chronic clinical manifestations 
of a progressive pathogenic process that is initiated by the inflammatory responses 
to dyslipidemia. The diverse metabolic and immune mechanisms at play in the 
thrombo-inflammatory pathophysiology of atherosclerosis are driven by disrup-
tions in the body’s native metabolism of cholesterol, triglycerides, and lipoproteins, 
with comorbid conditions and risk factors such as smoking, hypertension, and 
obesity promoting critical changes in cholesterol and lipoproteins that initiate a 
vicious cycle of lipoprotein accumulation, foam cell formation, and inflamma-
tory reaction. The fact that so many immune cell lines and metabolic factors play 
important roles in the development of atherosclerosis serves as a pool of current 
and potential future targets for therapies in the primary and secondary prevention 
of dyslipidemia and ASCVD.
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